Eli Lilly has promoted Anne White to President of its oncology business, replacing Sue Mahony.
White is currently vice president of portfolio management, Chorus and Next Generation Research & Development.
She has more than 25 years of experience in the pharmaceutical industry, serving in leadership roles in oncology, neuroscience, infectious disease drug development and process transformation.
White also worked in biotech, having founded and led a start-up company in oncology drug development with partnerships with the Moffitt Cancer Centre and the National Cancer Institute.
“Anne brings a wealth of experience, expertise and leadership to our executive team,” said Chairman and CEO, David A. Ricks.Ricks.
“She has led and delivered against our Next Generation Development objectives, accelerating medicines to patients and playing a key role in our recent R&D productivity.
“Her experience leading significant change transformation within the company will be incredibly valuable as we look toward the future.”